Now showing items 45-64 of 84

      Integrated Drug Reviews at the US Food and Drug Administration-Legal Concerns and Knowledge Lost. [1]
      Integrated Drug Reviews at the US Food and Drug Administration-Reply [1]
      Integrating multiple data sources (MUDS) for meta-analysis to improve patient-centered outcomes research: a protocol for a systematic review [1]
      Is this trial misreported? Truth seeking in the burgeoning age of trial transparency [1]
      Medical response to Trump requires truth seeking and respect for patients [1]
      Multisystem failure: the story of anti-influenza drugs [1]
      Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data [1]
      Neuraminidase inhibitors--the story behind the Cochrane review [1]
      No correction, no retraction, no apology, no comment: paroxetine trial reanalysis raises questions about institutional responsibility [1]
      Noninferiority Trials [letter to the editor] [1]
      North American regulatory agencies can and should make clinical trial data publicly available [1]
      Open data 5 years on: a case series of 12 freedom of information requests for regulatory data to the European Medicines Agency [1]
      Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments [1]
      Pandemrix vaccine: why was the public not told of early warning signs? [1]
      Patient consent to publication and data sharing in industry and NIH-funded clinical trials [2]
      Popular and scientific attitudes regarding pandemic influenza [1]
      The possible harms of statins: What do product labels, patient package inserts, and pharmacy leaflets tell us? [1]
      Preventing flu-like illness: Reason for optimism [1]
      The problem with US website for collecting adverse events after vaccination is resolved [1]
      Putting GlaxoSmithKline to the test over paroxetine [1]